nadunolimab
cantargia
['nadunolimab']
#asco22 abstract 9020 from dr. astrid paulus was a phase i/ii study of nadunolimab, anti-il1rap, with gem/cis. rr 53%, similar across histology, with mdor 5.8m and mos 13.7m 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him